Overview

• The new financing brings Assort’s total funding to $102 million, with Lightspeed leading and participation from returning backers First Round and Chemistry alongside Felicis, A*, Liquid 2 Ventures, and Quiet.
• Assort’s platform deploys AI agents across phone, SMS, and web to handle scheduling, prescription refills, lab results, and other patient‑facing front‑office tasks.
• The company reports a corpus of roughly 42 million patient interactions, support for more than 1.2 million configurable workflows, and direct integrations with most major EHR systems.
• Investor and company case studies describe reductions in front‑desk spend, lower call abandonment, higher show rates, and patient satisfaction scores surpassing human operators, though these metrics are self‑reported.
• Lightspeed frames adoption as a compounding flywheel and says the company is expanding toward a patient‑experience operating system spanning intake through follow‑up and billing.